Literature DB >> 16931506

SMN1 gene, but not SMN2, is a risk factor for sporadic ALS.

P Corcia1, W Camu, J-M Halimi, P Vourc'h, C Antar, S Vedrine, B Giraudeau, B de Toffol, C R Andres.   

Abstract

BACKGROUND: SMN1 gene deletions cause spinal muscular atrophy, and SMN2 gene deletions have been associated with sporadic lower motor neuron diseases.
OBJECTIVES: To study the frequency of abnormal SMN1 gene copy numbers and to determine whether SMN2 gene modulates the risk of amyotrophic lateral sclerosis (ALS) or the duration of evolution.
METHOD: The authors studied SMN1 and SMN2 genes in 600 patients with sporadic ALS and 621 controls using a quantitative PCR method.
RESULTS: The authors found an association of ALS with an abnormal copy number (one or three copies) of SMN1 gene (p < 0.0001) with an OR of 2.8 (1.8 to 4.4, 95% CI). There was no association with SMN2 copy numbers and no effect of SMN2 copies on the duration of evolution in ALS independently of SMN1 copy number.
CONCLUSION: Abnormal SMN1 gene copy numbers are a genetic risk factor in sporadic amyotrophic lateral sclerosis. There was no modulator effect of the SMN2 gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931506     DOI: 10.1212/01.wnl.0000233830.85206.1e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

Review 1.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

2.  Homozygous SMN2 deletion is a protective factor in the Swedish ALS population.

Authors:  Philippe Corcia; Caroline Ingre; Helene Blasco; Rayomand Press; Julien Praline; Catherine Antar; Charlotte Veyrat-Durebex; Yves-Olivier Guettard; William Camu; Peter M Andersen; Patrick Vourc'h; Christian R Andres
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

Review 3.  Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges.

Authors:  Giuseppe Marangi; Bryan J Traynor
Journal:  Brain Res       Date:  2014-10-12       Impact factor: 3.252

4.  Nuclear localization of human SOD1 and mutant SOD1-specific disruption of survival motor neuron protein complex in transgenic amyotrophic lateral sclerosis mice.

Authors:  Barry Gertz; Margaret Wong; Lee J Martin
Journal:  J Neuropathol Exp Neurol       Date:  2012-02       Impact factor: 3.685

5.  Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers.

Authors:  Marka van Blitterswijk; Bianca Mullen; Michael G Heckman; Matthew C Baker; Mariely DeJesus-Hernandez; Patricia H Brown; Melissa E Murray; Ging-Yuek R Hsiung; Heather Stewart; Anna M Karydas; Elizabeth Finger; Andrew Kertesz; Eileen H Bigio; Sandra Weintraub; Marsel Mesulam; Kimmo J Hatanpaa; Charles L White; Manuela Neumann; Michael J Strong; Thomas G Beach; Zbigniew K Wszolek; Carol Lippa; Richard Caselli; Leonard Petrucelli; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Ian R Mackenzie; William W Seeley; Lea T Grinberg; Bruce L Miller; Kevin B Boylan; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2014-05-02       Impact factor: 4.673

Review 6.  Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept.

Authors:  Vladimir N Uversky
Journal:  Expert Rev Proteomics       Date:  2010-08       Impact factor: 3.940

Review 7.  Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments.

Authors:  Luc Dupuis; Andoni Echaniz-Laguna
Journal:  Curr Drug Targets       Date:  2010-10       Impact factor: 3.465

8.  Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics.

Authors:  Silke Schmidt; Kelli D Allen; Valerie T Loiacono; Barbara Norman; Catherine L Stanwyck; Kristina M Nord; Christina D Williams; Edward J Kasarskis; Freya Kamel; Valerie McGuire; Lorene M Nelson; Eugene Z Oddone
Journal:  Neuroepidemiology       Date:  2008-04-18       Impact factor: 3.282

9.  SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity.

Authors:  Tie Zou; Raju Ilangovan; Furong Yu; Zuoshang Xu; Jianhua Zhou
Journal:  Biochem Biophys Res Commun       Date:  2007-10-25       Impact factor: 3.575

Review 10.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.